OLD Point Trust & Financial Services N A Buys Shares of 5,531 Bristol-Myers Squibb (NYSE:BMY)

OLD Point Trust & Financial Services N A bought a new stake in shares of Bristol-Myers Squibb (NYSE:BMY) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 5,531 shares of the biopharmaceutical company’s stock, valued at approximately $284,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Northwest Financial Advisors bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $27,000. Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $34,000. VisionPoint Advisory Group LLC grew its holdings in shares of Bristol-Myers Squibb by 300.5% during the third quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 553 shares during the last quarter. Turtle Creek Wealth Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $40,000. Finally, Wetzel Investment Advisors Inc. purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $40,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Price Performance

Shares of BMY stock traded up $0.60 on Friday, hitting $41.48. 13,665,456 shares of the stock traded hands, compared to its average volume of 14,074,232. The firm has a market cap of $84.08 billion, a price-to-earnings ratio of -13.38, a PEG ratio of 13.84 and a beta of 0.43. Bristol-Myers Squibb has a 52 week low of $39.91 and a 52 week high of $66.38. The firm has a 50 day simple moving average of $45.50 and a two-hundred day simple moving average of $48.98. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company’s revenue was up 4.7% on a year-over-year basis. During the same period last year, the firm earned $2.05 EPS. As a group, equities research analysts predict that Bristol-Myers Squibb will post 0.59 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on BMY shares. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. BMO Capital Markets cut their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Wells Fargo & Company raised their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. Finally, StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 23rd. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $60.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.